AI-based Clinical Trials Solution Provider Market (2026 - 2033)

AI-based Clinical Trials Solution Provider Market Summary

The global AI-based clinical trials solution provider market size was valued at USD 2.8 billion in 2025 and is projected to grow from USD 3.5 billion in 2026 to USD 17.1 billion by 2033, at a CAGR of 22.1% from 2026 to 2033. The North America market dominated with a revenue share of more than 43.0% in 2025. The growing adoption of AI-based platforms to enhance the efficacy and productivity of trials at various stages drives the market for AI-based clinical trial solution providers.

Supportive initiatives by the public and private sectors for different therapeutic areas are crucial in driving market growth. Furthermore, market players undertake several strategic initiatives to expand in the market. For instance, in March 2025, Tempus AI announced the acquisition of Deep 6 AI, aiming to expand its capabilities in clinical trial recruitment and real-world evidence generation through Deep 6 AI’s technology and analyze structured and unstructured electronic medical record data across a network of more than 750 provider sites.

Using AI in drug trials enhances the clinical outcomes, cost, and time required for drug trials, as drug development is a cost-intensive and time-consuming process. For instance, in December 2025, Accenture announced a strategic investment through Accenture Ventures in Ryght AI. While addressing existing challenges in clinical trial processes, Rhyght AI’s AI Site Twin platform develops digital models of clinical research sites, accessing historical performance, patient demographics, and operational data in real time. Such developments are key to the growth of this market.

Moreover, AI is instrumental in reducing bias in medical data. For instance, Genentech partnered with Stanford University to employ an open-source AI system to mitigate bias in drug trials. In addition, as the industry shifts from traditional to technology-based approaches, major pharmaceutical companies are increasingly adopting AI in clinical trials, thereby driving market growth.

Furthermore, the rising penetration of AI in drug trials and the availability of AI-based solutions in different aspects of clinical trials, such as patient enrichment & enrollment, drug trial design, investigator & site selection, medication adherence, and patient monitoring, among others, are fueling the market growth. Patient eligibility and enrollment are some of the important steps for the success of the overall drug trial. As per the research, 85% of the drug trials are stalled during patient recruitment, and 30% end early due to recruitment failure. The AI-based platforms are beneficial in lowering this hindrance. Hence, numerous researchers use AI for drug trials, fostering market growth.

Analyst Perspective

The AI-based clinical trials solution provider market is anticipated to experience substantial growth driven by the focus of multiple companies on reducing drug development costs, increasing trial complexities, and the ability of AI-powered solutions to improve patient recruitment processes. The growing adoption of AI-powered platforms for trial design optimization, patient recruitment, site selection, and real evidence generation is likely to contribute to further growth of this industry. Strategic acquisitions initiated by key players and collaboration among technology providers, pharmaceutical companies, and research organizations are accelerating market opportunities and expansion. However, certain challenges, such as data privacy, government regulations, algorithm transparency, and the integration of AI solutions within the existing healthcare systems, slow the market growth

Case Study: Clinical Trial Organizations Adopting AI to Enhance Patient Identification

A clinical trial organization aimed to reduce the time required to identify eligible patients by transitioning from manual chart reviews.

Problem:

• Research coordinators typically use structured data like ICD codes to identify qualified patients for clinical trials.
• Clinicians then review and combine this data with information from patient charts.
• This manual process is time-consuming, takes hundreds of hours, and is prone to inefficiencies and errors.
• As a result, 40% of clinical trial sites under-enroll compared to their plans, and 10% of sites fail to enroll a single patient.

Goal:

The customer aimed to determine if Mendel could replace manual chart reviews to achieve two objectives:

Test:

• The organization manually reviewed 5,000 charts across two clinical sites for an oncology trial, identifying 26 eligible patients in one week.
• Using Mendel’s clinically smart search and advanced query builder, the organization indexed 17,354 patients' clinical data in the same two sites within three days.

Result:

Clinical Trial Phase Insights

The Phase II segment dominated the market with a revenue share of 45.0% in 2025, owing to the presence of numerous registered clinical trials active in the second phase. The growing use of AI-based tools for data collection and analysis in drug trials is contributing significantly to the segment's growth. In addition, this segment commands a higher revenue share because it facilitates the development, refinement, and validation of measures for AI-based tools during this phase. Some of the developments associated with AI technology approvals for clinical trials also contribute to the growth of this market. For instance, in December 2025, PathAI, Inc. global company engaged in the AI-powered pathology industry, announced that its AIM-MASH AI Assist has received qualified status through the Drug Development Tool (DDT) Biomarker Qualification Program.

However, the Phase-I segment is expected to witness the fastest growth over the forecast period. The increasing complexity and costs of early-stage drug development necessitate more efficient and accurate trial methodologies, which AI-based solutions provide. These solutions enhance patient recruitment, optimize trial design, and improve data analysis, accelerating drug development. Moreover, the high failure rates in Phase I trials drive the demand for AI tools to predict outcomes better and identify potential issues early.

Therapeutic Application Insights

The oncology segment dominated the market with the largest revenue share of over 21.0% in 2025. The high prevalence of cancer globally and the large number of drug trials in the field of oncology are contributing to the adoption of AI-enabled technologies. Furthermore, numerous players are designing and adopting AI tools for oncology-based clinical trials, driving the segment growth. For instance, in April 2026, Worldwide Clinical Trials, one of the global Contract Research Organizations (CROs), announced furthering its strategic partnership with Medidata, a clinical trial solutions provider, and embraced Medidata Plus, equipped with a full AI layer of the Medidata Platform, binding the broad AI capabilities of virtual companion Dot. Such developments highlight the significance of partnerships and collaborations in the further growth of this industry.

The cardiovascular disease (CVD) segment is expected to grow at the fastest CAGR over the forecast period. The market growth is attributed to the high prevalence and significant mortality associated with CVD, which drives substantial investment in research and development. Moreover, the increasing penetration of AI-based platforms for analyzing CVDs using a new approach is a major factor contributing to segment growth. Additionally, the ability of AI to integrate and analyze diverse data sources, such as genomics, imaging, and electronic health records, facilitates more precise and personalized treatment approaches, further boosting the adoption of AI technologies in this segment.

End Use Insights

The pharmaceutical companies segment dominated the market, with the largest share of over 64.0% in 2025. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers, to identify new drug targets, and the overall process of drug development and clinical trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players collaborate with the AI vendor to leverage AI technology for R&D and the overall drug discovery process, driving growth. In May 2026, Parexel International Corporation, a global clinical development partner that provides clinical and consulting solutions, announced the launch of ParexelAI, a proprietary suite of human-led AI services and capabilities designed for deployment across the clinical development lifecycle.

However, the other segment is expected to grow at the fastest CAGR over the forecast period, owing to the rising trend of adoption of AI-enabled solutions by contract research organizations and government agencies, among others. The rising participation of CROs and other organizations in developing and adopting AI-based platforms and technologies useful in drug discovery and development, along with clinical trials, is anticipated to boost the market growth over the forecast period.

Regional Insights

The North America AI-based clinical trials solution provider industry dominated the global market with a revenue share of more than 43.0% in 2025. The growth is due to its advanced healthcare infrastructure, substantial investments in AI and biotechnology, and the presence of leading pharmaceutical companies. In February 2024, using funds from Genome Canada and data from the OICR-supported Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE) clinical trial, the Ontario researchers team designed a software platform, PMATCH. This platform utilizes machine learning and AI to match patients with precision medicine trials in near real-time. PMATCH compares detailed genomic and health data with clinical trial eligibility requirements and recommends trials for specific patients based on the latest cancer research.

U.S. AI-based Clinical Trials Solution Provider Market Trends

The U.S. AI-based clinical trials solution provider industry is primarily driven by technological advancements, leading prominent players to launch new products. For instance, in September 2025, Medable launched Agent Studio, an agentic AI platform for clinical development. Such developments strengthen the growth potential of the U.S. AI-based clinical trials solution provider market. It also launched CRA Agent, precisely designed for clinical trial monitoring. The presence of multiple companies engaged in clinical developments and AI technology for the healthcare industry across the U.S. is expected to fuel growth in the forecast period.

Europe AI-based Clinical Trials Solution Provider Market Trends

The AI-based clinical trials solution provider industry growth is attributed to technological advancements, the availability of advanced healthcare infrastructure, and supportive initiatives by regulatory authorities in the region. For instance, EFPIA backs the European Medicines Regulatory Network's (EMRN) measured approach to AI, which incorporates existing methods, research practices, and established requirements for other drug development tools, such as traditional statistical methods and model-informed drug development.

The UK AI-based clinical trials solution provider industry recorded a significant market share in 2025, owing to the development of AI-based solutions for clinical trials in various healthcare domains. For instance, in June 2024, a team led by UCL and Moorfields Eye Hospital researchers developed a new AI system to reduce the cost and time of recruiting patients for clinical trials targeting advanced age-related vision loss.

The AI-based clinical trials solution provider industry in Germany is witnessing investments in technological advancements in wearable pulse oximeters, which is driving the market growth. For instance, in November 2025, Valo Health announced a collaboration with Merck KGaA, Darmstadt, Germany, aimed at advancing the discovery and development of novel treatments for Parkinson’s and other diseases. This partnership aims to leverage Valo’s AI-integrated human biology and drug discovery platforms to help in the identification of diseases and accelerate the generation of preclinical drug candidates. Such developments are anticipated to facilitate market growth during the forecast period.

Asia Pacific AI-based Clinical Trials Solution Provider Market Trends

The AI-based clinical trials solution providers industry in the Asia Pacific is expected to grow at the fastest CAGR during the forecast period, owing to the increasing adoption of AI-based tools and supportive governmental initiatives across the healthcare sector. Clinical trial recruitment is rapidly expanding in Asia due to a sizable patient base and lower trial costs. Moreover, the Asia-Pacific region is favored by biotechnology firms across various clinical phases for its rapid patient enrollment capabilities, particularly in fields such as infectious diseases, oncology, metabolic conditions, immune-oncology, and rare diseases. The region offers cost-effective clinical research opportunities and boasts experienced investigators and research teams, further enhancing its attractiveness to global biotechnology companies.

The Japan AI-based clinical trials solution providers industry  is driven by the increasing efforts of universities and market players to integrate AI-based solutions in clinical trials. As Japan faces unique demographic and structural bottlenecks, multiple universities and companies are co-developing technologies to move away from traditional research and adopt novel approaches.

The AI-based clinical trials solution providers industry in Australia is expected to grow significantly during the forecast period, owing to the increasing number of strategic initiatives market players undertake. In January 2025, Ryght Inc. and one of the cancer care providers, Cancer Research South Australia (CRSA), announced a partnership aimed at advancing the cancer clinical trials in South Australia. Such strategic initiatives are key to the growth potential of this market.

Key AI-based Clinical Trials Solution Provider Company Insights

The growing market demand is expected to attract new entrants in the future, driven by rising awareness and acceptance of AI-based technologies for clinical trials. Key market players are also expanding their solution portfolio through strategic initiatives such as mergers, acquisitions, collaborations, and increased R&D investments in AI-driven clinical trial platforms. For instance, in May 2026, Roche announced that it had entered into an agreement to acquire PathAI, one of the key companies in the AI-powered digital pathology platform. This is expected to enhance Roche’s capabilities through PathAI’s advanced AI platform, which may help accelerate biomarker discovery, develop novel diagnostic tools, and more.

Key AI-based Clinical Trials Solution Provider Companies

The following are the leading companies in the AI-based clinical trials solution providers market. These companies collectively hold the large market share and dictate industry trends.

• Unlearn.ai, Inc.

• Saama

• Antidote Technologies, Inc.

• Phesi

• Tempus AI, Inc.

• Innoplexus (Partex NV)

• Mendel.ai,

• intelligencia.co

• Median Technologies

• SymphonyAI

• BioAge Labs, Inc.

• AiCure

• Consilx

• Paradigm Health.

• Symplr

• PHARMASEAL

• Ardigen S.A.

• Trials.ai

• Koneksa Health

• Euretos

• BioSymetrics, Inc.

• Verily Health

• Aitia

• IBM Corporation

• Recursion

Recent Developments

• In April 2026, Fortrea launched Fortrea Intelligent Technology (FIT), which is an AI-enhanced technology suite developed to transform clinical trial operations. This platform is set to integrate AI-powered workflow automation, near-real-time operational insights, and oversight tools to improve trial quality, productivity, and execution efficiency.

• In May 2026, Incyte initiated a strategic collaboration with Edison Scientific in order to employ the Edison’s AI-powered research platform, Kosmos AI, to improve discovery and development work.

• In October 2025, Saama launched Tables, Listings, and Figures (TLF) Analyzer, equipped with Saama’s AI-powered document generation solution compatibility, capabilities to understand numbers, graphs, and texts, and providing insights through summarizing complex graphs.

AI-based Clinical Trials Solution Provider Market Report Scope

Global AI-based Clinical Trials Solution Provider Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AI-based clinical trials solution provider market report based on therapeutic applications, clinical trial phase, end use, and region:

• Therapeutic Applications Outlook (Revenue, USD Billion, 2021 - 2033)

  • Oncology

  • CVD

  • Neurological Diseases or conditions

  • Metabolic diseases

  • Infectious diseases

  • Others

•   Clinical Trial Phase (Revenue, USD Billion, 2021 - 2033)

  • Phase-I

  • Phase-II

  • Phase-III

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Pharmaceutical Companies

  • Academia

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait